

May 1, 2008

APA DSM-V Work Group Member

Name, Degree: Deborah Blacker, M.D., Sc.D.

Role(s) in Work Group: Member, Neurocognitive Disorders Work Group

Institutional Affiliation(s): Mass General Hospital, Harvard Medical School, Harvard School of Public Health

City, State: Boston, MA

Biographical Sketch:

Deborah Blacker, MD, ScD

Member, Neurocognitive Disorders Work Group

Assistant Vice Chair for Research and Director, Gerontology Research Unit, Massachusetts General Hospital

Associate Professor of Psychiatry, Harvard Medical School; Associate Professor of Epidemiology, Harvard School of Public Health

Boston, MA

Dr. Blacker is a geriatric psychiatrist and epidemiologist who directs the Gerontology Research Unit at Massachusetts General Hospital, where she also serves as psychiatrist for the Mass Alzheimer's Disease Research Center and Assistant Vice Chair for Research in the Department of Psychiatry. She is Associate Professor of Psychiatry at Harvard Medical School. She is also actively involved in teaching and methodologic research at the Harvard School of Public Health, where she directs the Psychiatric Epidemiology concentration, and is Associate Professor in Epidemiology. Her primary work is aimed at locating genes that contribute to risk for Alzheimer's disease, including several different projects to collect, evaluate, and follow clinical samples for the study of Alzheimer's genetics. She is also involved in studies aimed at early recognition of Alzheimer's disease using clinical, neuropsychological, and neuroimaging methods, and understanding the genetic and environmental risk factors affecting the transition from mild memory difficulties to dementia. She serves on the APA's work group to revise the Practice Guidelines for Dementia, the Board of Directors of the Massachusetts and New Hampshire Alzheimer's Association, multiple research advisory boards, and the editorial boards of the *American Journal of Geriatric Psychiatry* and *Experimental Gerontology*.

Dr. Blacker received her bachelor's degrees from Stanford University and her medical degree from Harvard Medical School. She completed her psychiatric residency at Massachusetts General Hospital in Boston, after which she completed her doctorate in Epidemiology at the Harvard School of Public Health.

UNCOMPENSATED AFFILIATIONS WITH NON-PROFIT OR ADVOCACY ORGANIZATIONS THAT MAY HAVE A DIRECT OR INDIRECT INTEREST IN PSYCHIATRIC DIAGNOSIS, TREATMENT, OR THE DSM-V : CALENDAR YEARS 2005, 2006, 2007, AND FOR 2008, ACTIVITIES TO DATE AND COMMITMENTS FOR REMAINDER OF YEAR.

Non-Profit and Advocacy Organizations	Year(s)	Role
Medical and Scientific Advisory Board, Massachusetts Alzheimer's Association	2005-2008	Member
Board of Directors, Massachusetts Alzheimer's Association	2006-2008	Member

The two tables below represent Dr. Blacker's disclosure of significant interests and affiliations for: (1) The full calendar years of 2005, 2006, and 2007; and (2) for 2008, interests and affiliations to date and commitments for remainder of the year.

Dr. Blacker has agreed that, from the time of approval through the publication of DSM-V, projected in 2012, (his/her) aggregate annual income derived from industry sources (excluding unrestricted research grants) will not exceed \$10,000 in any calendar year.

<p>KEY NUMBER:</p> <p>1. Consultation Fees (include scientific advisory boards)</p> <p>2. Full- or Part-time Employee</p> <p>3. Industry-related Grant-Research Support received or pending</p> <p>4. Honoraria (includes Speakers' Bureau)</p> <p>5. Stock or other financial options</p>	<p>6. Expert testimony</p> <p>7. Royalties (including right to share of revenue or profit from pharmaceutical, device or other development or product)</p> <p>8. Patents received or pending</p> <p>9. Officer, director/trustee, executive (specify)</p> <p>10. Other (specify)</p>
---	--

DISCLOSURE OF SIGNIFICANT INTERESTS FOR 2005, 2006, AND 2007

Commercial or Other Organization	Year(s)	Key #(s)
Glaxo-Smith Klein, Advisory Board on Genetic Testing for possible clinical use of rosiglitzone (\$2100 + reimbursement for parking and local travel by car--<\$50)	2007	1

DISCLOSURE OF SIGNIFICANT INTERESTS TO DATE FOR 2008 AND COMMITMENTS FOR REMAINDER OF YEAR

Commercial or Other Organization	Year(s)	Key #(s)
Glaxo Smith Klein, research grant to look at impact of inclusion/exclusion criteria on recruiting for Alzheimer's disease clinical trials. Co-investigator receiving no salary or funding (mentoring junior investigator)	2008	3